Tracking Transplanted Stem Cells Using Magnetic Resonance Imaging and the Nanoparticle Labeling Method in Urology

Figure 2

Intravascular delivery of stem cells (HB1.F3.CD) targeting prostate cancer. (a) Schematic illustration of inducing prostate cancer using TRAMPC2, a systemic injection of HB1.F3.CD cells, and migration of the gene-modified stem cells toward the prostate cancer. Blue = TRAMPC2; red = HB1.F3.CD cells. (b) X-gal staining of induced prostate cancer 2 days after injecting HB1.F3.CD cells. Arrow indicates the cells. (c) Magnetic resonance imaging (MRI) of prostate cancer 48 hr after injecting HB1.F3.CD cells into mice. Arrow indicates the cells (scale bar, 100 μm). HB1.F3, neural stem cells; CD, cytosine deaminase.